|
- Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics
- Strengthening global CDMO strategy through strategic synergy with SK bioscience
- Sustainable growth expected, backed by European commercial manufacturing infrastructure and regulatory expertise
FRANKFURT, Germany, VIENNA and SEONGNAM, South Korea, Nov. 5, 2025 /PRNewswire/ -- IDT Biologika GmbH (IDT), the European subsidiary of SK bioscience, has embarked on a full-scale drive to expand its global contract development and manufacturing (CDMO) business in vaccines and biopharmaceuticals.
In October and early November, IDT participated in three of the industry's leading global events — the World Vaccine Congress Europe 2025 (WVC) in Amsterdam, the CPHI Frankfurt 2025 (Convention on Pharmaceutical Ingredients) in Germany, and the ongoing BIO-Europe 2025 in Vienna — where the company presented its comprehensive end-to-end manufacturing solutions and global partnership strategies, spanning from early development to full commercial production.
At WVC 2025, one of the world's largest vaccine conferences covering from R&D through commercialization, IDT held partnering meetings with global pharmaceutical companies and research institutes, highlighting its integrated capabilities in cell-culture and microbial-based processes, process development, quality validation, and fill-finish operations. Furthermore, the company shared how IDT developed a tailored in-house assay for high-sensitivity quantification and reliable sizing of host cell DNA.
Aligning with this year's congress theme, "Connecting Innovation from Research to Commercial Manufacture," the company emphasized its scalable CDMO platform supporting not only vaccines but also next-generation modalities such as gene and immune therapeutics and monoclonal antibodies.
During CPHI 2025, under the theme "Trusted Manufacturing Expertise with a Strong Partnership Commitment," IDT underscored its flexible production infrastructure, reliable supply chains, and extensive experience with European and global regulatory frameworks, reinforcing its position as a trusted CDMO partner for clients worldwide.
At BIO-Europe 2025, Europe's largest biopharmaceutical partnering conference, IDT focused on its drug-substance and drug-product manufacturing solutions for sterile injectables. The company showcased its aseptic production technologies, advanced process know-how, and integrated CDMO services supporting development through commercialization, while engaging in partnering discussions with global clients.
Through these three events, IDT strengthened its role as a strategic manufacturing partner providing tailored, end-to-end solutions, moving beyond traditional contract production. Leveraging its collaboration with SK bioscience, the company is accelerating efforts to expand global partnerships and project acquisitions.
"WVC, CPHI and BIO-Europe are key global stages for the vaccine and biopharmaceutical industry, where IDT demonstrated its manufacturing excellence and partnership capabilities," said Dr. Sally Choe, Co-CEO of IDT Biologika.
"Guided by our vision to be 'The reliable partner in creating a healthier world,' we will continue to advance customer-centric strategies and long-term partnerships to further strengthen our presence in the global CDMO market."
Since SK bioscience acquired a 60% stake in IDT Biologika last year, the two companies have integrated their development, manufacturing, and supply-chain operations across vaccines and advanced biopharmaceuticals, enhancing the competitiveness of their global CDMO network.
The combination of SK bioscience's recombinant protein and cell-culture technologies with IDT's European commercial manufacturing infrastructure and regulatory expertise has significantly improved operational efficiency and profitability. Industry observers expect IDT to achieve a full-year operating profit in 2025, marking a turnaround driven by this synergy.
Looking ahead, IDT Biologika plans to continue expanding its global CDMO footprint together with SK bioscience, reinforcing its position as a worldwide manufacturing hub for vaccines and advanced therapeutics and building a sustainable network spanning Europe, the Americas and Asia.
About SK bioscience
SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.
- SK bioscience Website
- SK bioscience Linkedin
Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)
Mooncheol Kim (MC_kim@sk.com)
- Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics
- Strengthening global CDMO strategy through strategic synergy with SK bioscience
- Sustainable growth expected, backed by European commercial manufacturing infrastructure and regulatory expertise
FRANKFURT, Germany, VIENNA and SEONGNAM, South Korea, Nov. 5, 2025 /PRNewswire/ -- IDT Biologika GmbH (IDT), the European subsidiary of SK bioscience, has embarked on a full-scale drive to expand its global contract development and manufacturing (CDMO) business in vaccines and biopharmaceuticals.
In October and early November, IDT participated in three of the industry's leading global events — the World Vaccine Congress Europe 2025 (WVC) in Amsterdam, the CPHI Frankfurt 2025 (Convention on Pharmaceutical Ingredients) in Germany, and the ongoing BIO-Europe 2025 in Vienna — where the company presented its comprehensive end-to-end manufacturing solutions and global partnership strategies, spanning from early development to full commercial production.
At WVC 2025, one of the world's largest vaccine conferences covering from R&D through commercialization, IDT held partnering meetings with global pharmaceutical companies and research institutes, highlighting its integrated capabilities in cell-culture and microbial-based processes, process development, quality validation, and fill-finish operations. Furthermore, the company shared how IDT developed a tailored in-house assay for high-sensitivity quantification and reliable sizing of host cell DNA.
Aligning with this year's congress theme, "Connecting Innovation from Research to Commercial Manufacture," the company emphasized its scalable CDMO platform supporting not only vaccines but also next-generation modalities such as gene and immune therapeutics and monoclonal antibodies.
During CPHI 2025, under the theme "Trusted Manufacturing Expertise with a Strong Partnership Commitment," IDT underscored its flexible production infrastructure, reliable supply chains, and extensive experience with European and global regulatory frameworks, reinforcing its position as a trusted CDMO partner for clients worldwide.
At BIO-Europe 2025, Europe's largest biopharmaceutical partnering conference, IDT focused on its drug-substance and drug-product manufacturing solutions for sterile injectables. The company showcased its aseptic production technologies, advanced process know-how, and integrated CDMO services supporting development through commercialization, while engaging in partnering discussions with global clients.
Through these three events, IDT strengthened its role as a strategic manufacturing partner providing tailored, end-to-end solutions, moving beyond traditional contract production. Leveraging its collaboration with SK bioscience, the company is accelerating efforts to expand global partnerships and project acquisitions.
"WVC, CPHI and BIO-Europe are key global stages for the vaccine and biopharmaceutical industry, where IDT demonstrated its manufacturing excellence and partnership capabilities," said Dr. Sally Choe, Co-CEO of IDT Biologika.
"Guided by our vision to be 'The reliable partner in creating a healthier world,' we will continue to advance customer-centric strategies and long-term partnerships to further strengthen our presence in the global CDMO market."
Since SK bioscience acquired a 60% stake in IDT Biologika last year, the two companies have integrated their development, manufacturing, and supply-chain operations across vaccines and advanced biopharmaceuticals, enhancing the competitiveness of their global CDMO network.
The combination of SK bioscience's recombinant protein and cell-culture technologies with IDT's European commercial manufacturing infrastructure and regulatory expertise has significantly improved operational efficiency and profitability. Industry observers expect IDT to achieve a full-year operating profit in 2025, marking a turnaround driven by this synergy.
Looking ahead, IDT Biologika plans to continue expanding its global CDMO footprint together with SK bioscience, reinforcing its position as a worldwide manufacturing hub for vaccines and advanced therapeutics and building a sustainable network spanning Europe, the Americas and Asia.
About SK bioscience
SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.
- SK bioscience Website
- SK bioscience Linkedin
Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)
Mooncheol Kim (MC_kim@sk.com)
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
Bringing exclusive sports and lifestyle travel to a new level of convenience and exclusivity
HONG KONG, April 1, 2026 /PRNewswire/ -- CSTS Enterprises, together with its subsidiary Connexus Travel, announced a strategic partnership with JETBAY, Asia's largest private jet charter platform, to deliver premium, bespoke travel and hospitality experiences to clients across Asia.
The collaboration brings together CSTS' worldclass sports and leisure hospitality expertise, Connexus Travel's 78 years of trusted corporate travel management, and JETBAY's award- winning door-to-door private aviation experience. Together, the companies will design seamless, high-end itineraries that connect sports fans, corporate clients, and luxury travellers to major global events — including the World Cup 2026, international sporting tournaments, and premium lifestyle destinations.
Under the partnership, CSTS will leverage JETBAY's extensive global aircraft network and on-demand charter services to enhance its end-to-end solutions for global clients.
From tailored matchday journeys and corporate travel programmes to bespoke leisure itineraries, our clients will enjoy fully integrated experiences combining stadium hospitality, premium ground services, and curated cultural activities — all backed by real-time support and dedicated relationship management.
"Travel is no longer about simply getting from A to B — it's about creating meaningful, shareable moments before, during, and after the event," said Abel Zhao, Chief Executive Officer and Executive Director of CSTS. "By partnering with JETBAY, we aim to elevate our clients' journeys beyond the ticket, delivering a truly integrated 'experience economy' where convenience, comfort, and exclusivity come together."
"Our goal is to make worldclass events more accessible to time sensitive business and leisure travellers, and this collaboration is a big step forward," said Vivian Zhang, Co- founder of JETBAY. "By partnering with CSTS, JETBAY can bring a new level of comfort and convenience to fans travelling for major global events."
The partnership reflects growing demand in the Asia market for premium, experience- driven travel products. As global sports and entertainment continue to drive audience engagement and travel demand, CSTS and JETBAY aim to become the go-to providers for clients seeking sophisticated, end-to-end solutions that marry worldclass travel technology with hands-on human service.
About CSTS Enterprises Inc.
Headquartered in Hong Kong, CSTS Enterprises is an innovative media, entertainment, sports, and travel-technology group. CSTS is dedicated to becoming a global expert in developing and managing innovative, end-to-end integrated marketing solutions and services that connect international intellectual properties – such as major sports and entertainment events – with regional and local brands.
At its core, CSTS is a provider of innovative solutions across corporate travel, integrated marketing, and advanced technology services. Through deep knowledge of the industry and advanced technologies, CSTS delivers tech-enabled efficiency and cost-effective travel programs, transforming corporate travel into a seamless, value-driven experience.
For more information, please visit https://csts-enterprises.com/ or follow our Linkedin for latest updates.
About Connexus Travel Limited
Connexus Travel (formerly known as Swire Travel) 全旅達國際旅遊有限公司, License No: (350001), one of the earliest Hong Kong-registered and award-winning travel agencies, has been a trusted household name for over 78 years. As an innovative travel management company in the region, it delivers seamless, tech-enabled experiences, combining personalized 24/7 support with innovative digital platforms. Connexus Travel offers a full spectrum of travel services—including corporate, leisure, MICE, and sports/lifestyle travel—and plays a key role in promoting global events like the FIFA World Cup and Formula 1.
Connexus Travel is a subsidiary of CSTS Enterprises.
About JETBAY
JETBAY is Asia's largest private jet charter platform, leveraging proprietary AI technology to provide clients with the most efficient and cost-effective private aviation solutions globally. Headquartered in Singapore and backed by over 20 years of industry expertise, JETBAY offers a seamless booking experience and unparalleled service through its international offices in New York, London, Dubai, Hong Kong, Jakarta, and Shanghai. The company is dedicated to upholding the highest standards of safety, privacy, and luxury for its discerning clientele.
Forward-Looking Statements
This press release contains statements that are forward-looking statements. These forward-looking statements can be identified by terminology such as "anticipate," "estimate," "forecast," "plan," "project," "potential," "continue," "ongoing," "expect," "aim," "believe," "intend," "may," "should," "will," "is/are likely to," "could" and similar statements. Statements that are not historical facts, including statements about CSTS's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. All information provided in this press release is as of the date of this press release, and CSTS does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Media Contacts
Wicky Yu
Corporate Communications, CSTS Enterprises Inc.
Phone: +852 2122 8545
Email: communications@csts-enterprises.com
Website: https://csts-enterprises.com/
Cody Lee Kar Hao
Branding and Marketing Manager, JETBAY
Phone: +65 6562 2988
Email: karhaolee@jet-bay.com
Website: https://www.jet-bay.com/
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CSTS Enterprises and JETBAY Announce Strategic Partnership to Elevate Sports and Leisure Travel Experiences
